Alzheimer’s Research UK, the world’s largest dedicated dementia research charity, has announced a £30 million Drug Discovery Alliance, launching three flagship Drug Discovery Institutes at the Universities of Cambridge, Oxford and UCL (University College London). The Drug Discovery Institutes will see 90 new research scientists employed in state-of-the-art facilities to fast-track the development of new treatments for Alzheimer’s disease and other dementias.
Eve, an artificially-intelligent ‘robot scientist’ could make drug discovery faster and much cheaper, say researchers writing in the Royal Society journal Interface. The team has demonstrated the success of the approach as Eve discovered that a compound shown to have anti-cancer properties might also be used in the fight against malaria.
The structure of sodium channels – which play an essential role in the functioning of heart and nerve cells – are different than previously believed. Researchers hope their discovery will lead to improvements in drugs that act on the sodium channel to treat a range of cardiac and pain conditions.
A new method which streamlines the design and construction of synthetic membrane pores could improve a range of scientific processes, including speeding up the development of new drugs, and enabling more efficient disease diagnosis through DNA sequence detection.
Cambridge researchers developing new therapies as part of a collaborative programme with industry.
A new collaboration based at the University of Cambridge will aim to discover and develop new medicines to treat liver disease.